Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Status:
Suspended
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in
combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk
myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell
transplant. It includes a randomized pilot sub-study during stage 1.